HOME >> MEDICINE >> NEWS
Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit

ss III or IV angina refractory to medical therapy who also had multivessel occlusive coronary artery disease not amenable to revascularization. Patients were treated in dose-escalating fashion at 200, 800 or 2,000 mg dose, injected directly into the heart muscle with a hypodermic needle after a mini-thoracotomy, a surgical incision in the chest wall.

Patients were followed for clinical events after one year by hospital records, follow-up visits or telephone contact. At the most recent follow-up, no patients had Class IV angina, and only three (11.5%) had Class II angina, while the remaining had Class I or II angina. Compared to baseline, average angina class decreased from 3.6 0.5 to 1.3 1.0 after the first year. This benefit persisted to 24 months when the mean angina class was 1.5 1.2 (p< 0.05).

Major clinical events such as death, myocardial infarction (MI, or heart attack) and repeat revascularization were uncommon during the first year but more frequent after one year at a rate consistent with the severity of the underlying disease in a population with advanced atherosclerosis. The majority of events were the result of progression of disease in areas of the heart remote from the site of injection.

Previous Clinical Data

Physicians who participated in the Phase I study published previous reports stating that the results demonstrated the safety of VEGF-2 and citing significant improvement in the exercise tolerance time in all dose groups. The study reports reflected that 80% of the patients treated experienced an improvement (decrease) in angina class of two or more levels and 40% of the patients experienced complete elimination of angina symptoms. Similarly, significant reductions in the number of angina episodes per week and the number of nitroglycerin tablets taken were observed. Given the invasive nature of this trial, there was not a control group that received a placebo.

The Phase I trial was followe
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
8-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. 14-year study finds that quitting smoking adds years to life
3. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
4. Cumulative trauma in adulthood can worsen health in later years
5. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds
6. Vioxx should have been withdrawn 4 years ago
7. Cancer burden seen even many years after diagnosis
8. Scientists meet to review Envisat results after two and a half years of operations
9. Study finds lung transplants increase survival of cystic fibrosis patients by more than four years
10. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years
11. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... Atlanta (PRWEB) , ... May 06, 2016 , ... From ... provider Presence Technology will share its insights on managing Customers Engagement at ... , At SpeechTek 2016, Presence Technology will deliver a Presentation on “5 ...
(Date:5/6/2016)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh, has written a new article this ... about helping to stop cancer. Yisrayl says there are too many suffering and dying from ... science industries will pay close attention and take action. The Pastor says that the root ...
(Date:5/6/2016)... ... ... “ Crossing Over: Affirmations of Faith in the Midst of the Dying ” ... vigil to glimpse into the supernatural as their lives ended. With her debut book, ... gain insight into providing care to terminal patients. , “I was inspired to ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... (LAIs), today announced a development collaboration with the Australian critical medicine company, ... disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits over ...
(Date:5/5/2016)... Palm Beach, Fla. (PRWEB) , ... May 05, 2016 , ... ... Vision Institute in San Diego, California. The laser eye center will now be called ... recognized surgeons and attentive staff will remain at the full-service facility to ensure that ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 /PRNewswire/ ... announced today that BiondVax,s CEO, Dr. Ron Babecoff , ... New York City . On ... at Pioneers 2016, a conference presented by Joseph Gunner ... Hotel. The BiondVax presentation that Dr. Babecoff will ...
(Date:5/4/2016)... 4, 2016 In March, ... series of free workshops across Africa ... requirements for Good Distribution Practices (GDP). Good Distribution ... that products are consistently stored, transported and handled under ... or product specification. Only a few years ago, there ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Ischemic Stroke Market and ... their offering.       (Logo: ... Acute Ischemic Stroke Market and Competitive Landscape ... Ischemic Stroke pipeline products, Acute Ischemic Stroke ...
Breaking Medicine Technology:
Cached News: